|
|
Article: Curis Achieves Milestone under Wyeth Collaboration.
- Article from:
- Business Wire
- Article date:
- March 23, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that it has achieved a development milestone under a collaboration with one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). The milestone is based on Wyeth's and Curis' continued progress in preclinical development of Hedgehog pathway agonists for the treatment of stroke, neurological and other disorders. The milestone will trigger a modest payment from Wyeth to Curis in accordance with the terms of their 2004 agreement.
The Hedgehog signaling pathway regulates the normal development of the brain and spinal cord. Wyeth and ...